Cogent Biosciences, Inc.
COGTDrugs in Pipeline
5
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Mar 2027
Market Overview
Stock performance and key metrics
2 upcoming, 0 past
COGT Earnings Report
EPS Est: $-0.55 | FQ end 2026-06
1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How COGT's past catalysts played out
CGT9486 plus sunitinib
Advanced Gastrointestinal Stromal Tumors
CGT9486
Gastrointestinal Stromal Tumors
bezuclastinib
Advanced Systemic Mastocytosis (AdvSM)
Bezuclastinib Tablets (Formulation A)
SSM
CGT4859
Intrahepatic Cholangiocarcinoma (Icc)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CGT9486 plus sunitinib | Phase 3 | Advanced Gastrointestinal Stromal Tumors | - | - |
CGT9486 | Phase 3 | Gastrointestinal Stromal Tumors | - | - |
bezuclastinib | Phase 2 | Advanced Systemic Mastocytosis (AdvSM) | - | - |
Bezuclastinib Tablets (Formulation A) | Phase 2 | SSM | - | - |
CGT4859 | Phase 2 | Intrahepatic Cholangiocarcinoma (Icc) | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Cogent Biosciences, Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Cogent Biosciences, Inc.'s (COGT) pipeline across Phase 3, Phase 2. Its lead program is CGT9486 plus sunitinib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Cogent Biosciences, Inc.'s next FDA catalyst?→
Cogent Biosciences, Inc.'s (COGT) next tracked catalyst is a Earnings expected August 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track COGT biotech catalysts?→
Add COGT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Cogent Biosciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.